Medtronic plc (MDT) is steadily expanding its global footprint within the Cardiovascular business, which should support its growth in the coming quarters. Within Neuroscience, the company is gaining shares in Cranial and Spinal technologies, backed by strong growth and competitor exit. Robust international expansion also remains encouraging for the stock. Meanwhile, ongoing macroeconomic volatilities, along with escalating expenses, may have an adverse impact on the company’s operations.In the past year, th ...